Certara, Inc. (CERT)

Market Cap	1.70B
Revenue (ttm)	372.80M
Net Income (ttm)	-31.08M
Shares Out	160.97M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	21.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159,208
Open	10.71
Previous Close	10.71
Day's Range	10.50 - 10.85
52-Week Range	9.41 - 19.87
Beta	1.53
Analysts	Buy
Price Target	15.92 (+51.04%)
Earnings Date	Nov 6, 2024

About CERT

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new dr...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 1,391
• Stock Exchange: NASDAQ
• Ticker Symbol: CERT
• Website: https://www.certara.com

Analyst Forecast

According to 7 analysts, the average rating for CERT stock is "Buy." The 12-month stock price forecast is $15.92, which is an increase of 51.04% from the latest price.

Price Target

$15.92

(51.04% upside)

Analyst Consensus: Buy